Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.8%

4 terminated out of 51 trials

Success Rate

84.0%

-2.5% vs benchmark

Late-Stage Pipeline

4%

2 trials in Phase 3/4

Results Transparency

33%

7 of 21 completed with results

Key Signals

7 with results84% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (13)
P 1 (7)
P 2 (7)
P 3 (1)
P 4 (1)

Trial Status

Completed21
Recruiting13
Unknown7
Active Not Recruiting5
Terminated4
Not Yet Recruiting1

Trial Success Rate

84.0%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT00001160Recruiting

Studies on Tumors of the Thyroid

NCT04948437Active Not Recruiting

Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer

NCT06316895RecruitingPrimary

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

NCT07140757Recruiting

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers

NCT02568267Phase 2Active Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT06235814Not ApplicableCompletedPrimary

Molecular Analysis for Precision Surgery in Thyroid Cancer Trial

NCT07354698Phase 4Not Yet RecruitingPrimary

Application of Mitoxantrone Hydrochloride Injection in Transoral Robotic Thyroid Cancer Surgery

NCT06133374RecruitingPrimary

Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples

NCT03899792Phase 1Active Not Recruiting

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

NCT04624477Active Not RecruitingPrimary

Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer

NCT05024929RecruitingPrimary

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

NCT04544111Phase 2Active Not Recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

NCT06439745CompletedPrimary

More Than 50% of Unifocal cN0 T1b/Small T2 Papillary Thyroid Carcinoma May Require Completion Thyroidectomy if Nodal Status is Evaluated

NCT01723202Phase 2Completed

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

NCT05752669CompletedPrimary

Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.

NCT03469011Phase 1TerminatedPrimary

A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.

NCT04129411Not ApplicableCompletedPrimary

Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

NCT06733740RecruitingPrimary

Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma

NCT06800482Not ApplicableRecruiting

A Study of Online Follow-up in Patients With Papillary Thyroid Cancer

NCT05132205Not ApplicableCompletedPrimary

Radiofrequency Ablation of Papillary Thyroid Microcarcinoma

Scroll to load more

Research Network

Activity Timeline